Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls

by Zacks Equity Research

Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.

Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug

by Zacks Equity Research

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.

ImmunoGen (IMGN) Q4 Earnings & Sales Top, Pipeline on Track

by Zacks Equity Research

ImmunoGen (IMGN) reports encouraging fourth-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.

Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

by Zacks Equity Research

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19

by Zacks Equity Research

Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

New Strong Sell Stocks for February 5th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates

by Zacks Equity Research

Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales. The company provides revenues guidance for 2021.

AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright

by Zacks Equity Research

AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull

by Zacks Equity Research

Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

by Zacks Equity Research

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.

What's in the Cards for Amgen (AMGN) This Earnings Season?

by Zacks Equity Research

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.

Regeneron (REGN) Reports Positive Data on Cocktail for COVID-19

by Zacks Equity Research

Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infection.

Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?

by Zacks Equity Research

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.

Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review

by Zacks Equity Research

Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

by Zacks Equity Research

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids

by Zacks Equity Research

FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

by Kinjel Shah

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

Sarepta (SRPT) Inks New Gene Editing Research Collaboration

by Zacks Equity Research

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.

Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment

by Zacks Equity Research

Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.